Feedback
Hemophilia B (F9) Deletion/Duplication
2010499
Ordering Recommendation

This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

Mnemonic
F9 DD
Methodology
Multiplex Ligation-dependent Probe Amplification
Performed
Varies
Reported
Within 14 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B). 
Specimen Preparation
Transport 3 mL whole blood. (Min: 2 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
 
Remarks
 
Stability
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable 
Reference Interval
By report
Interpretive Data
Background Information for Hemophilia B (F9) Deletion/Duplication:
Characteristics:
Severe deficiency of factor IX clotting activity is associated with spontaneous joint or deep tissue bleeding. Moderate or mild deficiency is associated with prolonged bleeding after tooth extractions, surgery, or injuries and recurrent or delayed wound healing.
Incidence:
1 in 25,000 males worldwide.
Penetrance:
100 percent in males and 10 percent in females.
Inheritance:
X-linked recessive.
Cause:
Pathogenic F9 gene mutations.
Clinical Sensitivity:
3 percent.
Methodology:
Multiplex Ligation-dependent Probe Amplification (MLPA) to detect large F9 deletions/duplications.
Analytical Sensitivity and Specificity:
99 percent.
Limitations:
Diagnostic errors can occur due to rare sequence variations. Large deletions/duplications in exon 1 may not be detected. Regulatory region mutations, deep intronic mutations, single base pair substitutions, and small deletions/duplications will not be identified.

Compliance Statement C: The performance characteristics of this test were validated by ARUP Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. ARUP is authorized under Clinical Laboratory Improvement Amendments (CLIA) and by all states to perform high-complexity testing. Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note
N/A
CPT Code(s)
81479
Components
Component Test Code*Component Chart NameLOINC
2010500Hemophilia B (F9) DelDup Specimen31208-2
2010501Hemophilia B (F9) DelDup Interp38896-7
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Christmas Disease
  • Factor IX Deficiency